INTRODUCTION {#S0001}
============

Advances in multiparametric magnetic resonance imaging (mp-MRI) have demonstrated an improvement in detection and characterization of clinically significant prostate cancer \[[@CIT0001]\]. Mp-MRI combines diffusion-weighted and, commonly, dynamic contrast-enhanced sequences, with conventional T2-weighted sequences. Introducing mp-MRI and MRI targeted biopsy as modalities to evaluate men at risk for prostate cancer may aid in better determining which men need a prostate biopsy and improve sampling in the performance of the biopsy, thereby allowing greater detection of clinically significant disease with fewer biopsy cores, more accurate risk stratification, and avoidance of the detection of indolent disease \[[@CIT0002], [@CIT0003]\]. MRI targeted biopsy may also allow for better risk stratification among men who are considering active surveillance. In this review we discuss limitations of the current prostate biopsy standard, components of the mp-MRI exam, techniques of MRI targeted biopsy, along with clinical applications and outcomes.

Current standard for prostate biopsy and limitations {#S20002}
----------------------------------------------------

The contemporary random 12-core systematic biopsy strategy relies on sampling efficiency for cancer detection and, as a result, is subject to sampling error. Although laterally directed cores within the peripheral zone increase detection, prostate cancers are frequently multifocal, small, intermingled with benign stroma, and not uniformly distributed within the gland \[[@CIT0004]\]. Consequently, clinically significant cancers frequently go undetected when employing the standard 12-core biopsy template. Under-sampling of the cancer during conventional TRUS-guided biopsy also leads to incorrect risk stratification of clinically significant tumors as low volume or low grade. Nearly three quarters of men over the age of 50 years harbor clinically insignificant prostate cancer at autopsy. These clinically insignificant cancers are often identified by chance during a systematic biopsy, contributing, in part, to the problem of over-detection and over-treatment of indolent prostate cancer. Repeat biopsy, performed to overcome sampling error, further increases the detection of clinically insignificant prostate cancer. The recent trend of overcoming sampling error through increasing core number at the time of biopsy, also further escalates the risk of identifying small, indolent cancers which may have little to do with the patient\'s PSA elevation \[[@CIT0004]\].

Components of a multiparametric prostate MRI exam {#S20003}
-------------------------------------------------

### T2-Weighted imaging

T2-weighted MR images, reflecting tissue water content, have high spatial resolution and clearly define the prostate\'s zonal anatomy, distinguishing the peripheral zone (high signal intensity) from the central zone (surrounding the ejaculatory ducts in the posterior prostate base and exhibiting decreased T2 signal intensity) and transition zones (surrounding the urethra, extending anteriorly and superiorly from the level of the verumontanum, and exhibiting heterogeneous, often swirled, signal-intensity) ([Figure 1](#F0001){ref-type="fig"}) \[[@CIT0005]\]. Furthermore, this sequence aids tumor staging by facilitating evaluation of extra-prostatic extension, seminal vesicle invasion, and neurovascular bundle invasion by the tumor. The sensitivity of MRI in detecting extra-prostatic extension or seminal vesicle invasion has improved to a range of 73 to 80% with a high specificity of 97--100%. Extra-prostatic extension as small as 0.5 mm at histopathology has been accurately detected \[[@CIT0006]\]. The peripheral zone of the prostate usually exhibits high signals on T2-weighted images. In contrast, peripheral zone tumors generally appear as round or oval foci of decreased signal using this sequence. The degree of intensity decrease differs with the Gleason score, with higher Gleason score components showing lower signal intensities \[[@CIT0007]\]. T2-weighted imaging alone results in false positive findings, as low signal intensity can also be the consequence of benign abnormalities including acute and chronic prostatitis, atrophy, scars, post-irradiation or hormonal treatment effects, hyperplasia, and post-biopsy hemorrhage. Because post-biopsy changes can mimic prostate cancer on T2WI, it is generally recommended to delay mp-MRI for at least 8 to 12 weeks after biopsy \[[@CIT0008]\]. Furthermore, low-grade tumors may be isointense to the high signal peripheral zone and therefore not well visualized using T2-weighted imaging. Cancer in the transition zone may be more difficult to discern than in the peripheral zone partly due to the heterogeneous appearance of BPH with areas of both increased and decreased signal intensity. In a recent meta-analysis, Tan et al. investigated the diagnostic performance of T2-weighted images alone in prostate tumor localization, demonstrating a sensitivity and specificity of 0.57--0.62 and 0.74--0.78, respectively \[[@CIT0009]\]. These moderate performance characteristics highlight the need for use of additional sequences to achieve accurate tumor detection and localization.

![Multiparametric MRI imaging incorporates T2-weighted, diffusion-weighted, and dynamic contrast-enhanced imaging to identify areas in the prostate suspicious for cancer based on anatomic and functional characteristics.](CEJU-69-00734-g001){#F0001}

### Diffusion-weighted imaging

Diffusion-weighted imaging (DWI) assesses the diffusion of water molecules within different tissues ([Figure 1](#F0001){ref-type="fig"}). Normal prostate glandular tissue has a higher water diffusion rate than cancer tissue owing to restricted diffusion in tightly packed cancer cells. Changing the amplitude of the diffusion-weighting gradients varies the degree of diffusion weighting, referred to as a 'b-value', for a given DWI sequence. At low b-values, DWI predominantly reflects water movement over larger length scales, mainly secondary to capillary perfusion, whereas at higher b-values, DWI interrogates movement over small length scales, such as within cells or intracellular organelles \[[@CIT0010], [@CIT0011]\]. There is a debate regarding the most appropriate b value to be used for DWI of the prostate. Historically, b values up to 800--1000 s/mm^2^ were used. However, recent studies report improved lesion detection using even higher b values of up to 2000 s/mm^2^ \[[@CIT0012]\]. In addition, the actual diffusion coefficient of water cannot be directly measured by MRI. Rather diffusion-weighted images must be acquired using at least two different b values, from which a diffusion coefficient can be calculated. The most widely applied coefficient in clinical practice is the apparent diffusion coefficient (ADC). The ADC map better reflects the diffusivity of water molecules than the directly acquired trace b value images themselves, which in fact reflect a combination of both diffusion weighting and T2 weighting ([Figure 1](#F0001){ref-type="fig"}). Prostate tumors generally demonstrate increased signal on high b value DWI as well as decreased ADC, given the association between tumor cellularity and restricted diffusion. ADC values derived from DWI images are inversely correlated with the Gleason score of lesions at biopsy or surgery \[[@CIT0013]\] however, the confidence intervals are widely overlapping, limiting the ability to use ADC as a surrogate to the Gleason score. The value of DWI for prostate cancer imaging has been established in numerous publications in recent years \[[@CIT0014]\].

### Perfusion imaging

During dynamic contrast-enhanced (DCE) MRI, a bolus of intravenous contrast medium (gadolinium) is injected and serial, rapid sequences are obtained ([Figure 1](#F0001){ref-type="fig"}). The objective is to demonstrate the increased enhancement of the prostate cancer compared with normal prostatic tissue, which correlates with tumor angiogenesis. Given the serial rapid imaging of the prostate, DCE-MRI allows assessment of contrast kinetics within focal lesions. Prostate tumors release factors that promote vessel formation and capillary permeability, thereby leading to more rapid enhancement than surrounding normal tissue \[[@CIT0015]\]. Prostate cancer typically enhances faster and to a greater extent than surrounding prostate, and will also show a more rapid washout of contrast in a fraction of cases. Typically, images are acquired sequentially at a rate of at least every 10 seconds and preferably \<7 seconds and for a total duration of at least 2 minutes \[[@CIT0015], [@CIT0016]\]. Even though prostatitis-related enhancement is usually diffuse and non-focal in nature, and BPH-related enhancement is often well-encapsulated and spherical, the non-specific nature of these patterns limits the utility of DCE findings in isolation, resulting in DCE often being applied largely as an adjunct to interpretations based primarily on findings on T2WI and DWI.

### Multiparametric-MRI

Although individual imaging sequences have utility in the detection of prostate cancer, results are optimized by multiparametric (mp) MRI, which combines all of the sequences in an integrated fashion to improve specificity ([Figure 1](#F0001){ref-type="fig"}). Mp-MRI offers superior diagnostic power for prostate cancer detection and can assist risk stratification based on lesion size, extent and ADC value \[[@CIT0017]\]. In one study, mp-MRI sensitivity exceeded 80% for detecting 0.2 cm^3^ of Gleason 4 + 3 or above and 0.5 cm^3^ of ≥ Gleason 3 + 4 \[[@CIT0018]\]. Adding DCE and/or DW imaging to T2-weighted MRI has been demonstrated to significantly improve sensitivity from 63% to 79--81% in the peripheral zone, while maintaining a stable specificity \[[@CIT0019]\]. A recent pooled data meta-analysis showed a specificity of 88%, sensitivity of 74%, with a negative predictive value of 65% to 94% when employing mp-MRI to detect prostate cancer \[[@CIT0020]\]. Furthermore, additional studies have highlighted the combined use of DW, DCE, and T2-weighted imaging to increase accuracy in detection of transition zone cancer compared to T2WI alone, from 64% to 79% \[[@CIT0021]\]. Mp-MRI has also shown to have greater accuracy in detection of recurrent prostate cancer after radiation \[[@CIT0022]\]. Nevertheless, given moderate specificity, mp-MRI findings require biopsy to confirm the presence of tumor and assess Gleason score \[[@CIT0017]\].

### Multiparametric-MRI prostate lesion scoring system

With the advent of mp-MRI as a tool to identify suspicious areas within the prostate, many grading schemes have evolved in order to assess the likelihood of cancer based on image characteristics. The Prostate Imaging Reporting and Data System (PI-RADS), recently updated to PI-RADS version 2.0, is a reporting scheme based on specific features of T2-weighted, DWI, and DCE sequences aimed to standardize prostate MRI reporting and grade suspicious regions of the prostate on a reproducible scale to represent their likelihood of harboring cancer foci ([Table 1](#T0001){ref-type="table"}) \[[@CIT0016], [@CIT0023]\]. For interpretation, PI-RADS provides explicit criteria for assigning a region of interest (ROI) a score from 1 to 5 for each sequence (T2WI, DWI, and DCE). These scores reflect the ROI\'s degree of abnormality on each particular sequence. An overall score from 1 to 5 is also assigned, reflecting the likelihood that the ROI reflects a clinically significant cancer. The prostate is divided into discrete anatomic regions (either 16 or 27 regions, based on models recommended by the ESUR/PI-RADS guidelines), and any identified individual lesions are assigned to these various regions.

###### 

PI-RADS 2.0 scoring criteria

  Assessment category   Peripheral zone   Transition zone                     
  --------------------- ----------------- ----------------- ----- ----- ----- -----
  1                     1                 Any               Any   Any   1     Any
  2                     2                 Any               Any   Any   2     Any
  3                     3                 Any               (-)   ≤ 4   3     Any
  4                     3                 Any               (+)   5     3     Any
  4                     Any               Any               Any   4     Any   
  5                     5                 Any               Any   Any   5     Any

Adapted from: American College of Radiology. MR Prostate Imaging Reporting and Data System version 2.0. Accessed June 2015, from <http://www.acr.org/Quality-Safety/Resources/PIRADS/>

Studies evaluating PI-RADS criteria through targeted biopsy have shown strong predictive ability in identifying the likelihood of prostate cancer, as well as correlation with Gleason score \[[@CIT0024], [@CIT0025], [@CIT0026]\]. Despite this, several institutions reporting outcomes of targeted biopsy have alternatively used Likert scales to assess pre-biopsy disease risk \[[@CIT0002], [@CIT0027]\]. While heterogeneous, most have generally been shown to predict the overall likelihood of cancer and likelihood of high-grade disease. Meng et al. demonstrated a significant stepwise increase in risk of Gleason ≥7 disease with increasing MRI suspicion score on a 5-point Likert scale \[[@CIT0003]\]. Salami et al. compared the predictive capability of mp-MRI scored on a Likert scale to the Prostate Cancer Prevention Trial risk calculator, and demonstrated a higher area under the curve for mp-MRI compared to the risk calculator \[[@CIT0028]\]. Several studies have also directly compared PI-RADS scoring of lesions to Likert scale scoring of the same mp-MRI studies, showing no difference in performance \[[@CIT0029], [@CIT0030], [@CIT0031]\]. The recent release of PI-RADS version 2.0 gives criteria for devising an overall score from 1--5 based on findings from the different sequences, thereby helping reproducibility in terms of overall suspicion scores, and may encourage more widespread adoption of this standardized reporting. Moreover, it has been recently shown that the second version of PI-RADS is only moderately reproducible \[[@CIT0032]\]. On average, it shows good correlation with histopathologic results and high sensitivity for clinically significant disease, but specificity is low. In a recent review, no recommendations regarding which PI-RADS suspicion score lesions require biopsy and which can be observed could be provided because of heterogeneity of the studies reported throughout the literature \[[@CIT0026]\]. PI-RADS will continue to evolve as more experience is gained.

### Technique of MRI targeted biopsy

Currently three techniques of MRI guidance are available for targeted prostate biopsy: visual estimation TRUS-guided biopsy (also referred to as cognitive fusion), in-bore MRI guided biopsy, and software based co-registration guided biopsy with MRI to ultrasound fusion. Each method possesses its own advantages and disadvantages but to date, no prospective comparison of the three methods has been made. Visual estimation TRUS-guided biopsy, in which the ultrasound operator simply aims the biopsy needle at the prostate area where the previously reviewed MRI demonstrates a lesion, allows rapid adaption of MRI-targeted biopsy into clinical practice and requires no additional equipment beyond the MRI and a conventional transrectal ultrasound. The technique does carry a learning curve in that there is no real-time feedback regarding needle placement accuracy and the biopsy is prone to human error without actual image overlay. The effectiveness of visual estimation targeted biopsy in detecting prostate cancer varies between studies, likely due to investigator experience and variable practices in imaging approach. However, a prospective study by Wysock et al. comparing MRI-US fusion versus visual estimation demonstrated that fusion biopsy was more often histologically informative than visual targeting, revealing more nonbenign pathology than, but did not increase cancer detection \[[@CIT0033]\]. A trend toward increased detection with fusion biopsy was observed across all study subsets.

In bore MRI-guided biopsy is performed within the MRI gantry, by a radiologist, who plans the biopsy based upon an acquired MRI and confirms biopsy needle localization under repetitive MRI sequences. Typically only a few targeted cores are taken and systematic sampling is not readily performed, leaving normal appearing prostate tissue unsampled. The advantages of this method are fewer sampled cores, visual feedback regarding the accuracy of needle placement, and, in theory, the reduced detection of insignificant tumors. However, the biopsy requires a longer procedure time (1--2 hours), has a high cost, and is resource-intensive in that it requires prolonged access to a MRI scanner.

Software co-registered MRI targeted TRUS biopsy allows the operator to image the prostate using ultrasound, while a previously performed and annotated MRI is fused with the real-time ultrasound using a digital overlay, creating a three-dimensional reconstruction of the prostate, on which the previously marked ROI are identified. Spatial tracking of the ultrasound probe through mechanical or electromagnetic means allows accurate placement of the needle guide relative to the three-dimensional reconstruction ([Figure 2](#F0002){ref-type="fig"}). MRI-US-fusion biopsy potentially has greater reproducibility due to less operator dependence by providing real time feedback of actual biopsied locations. The disadvantages include the cost of an additional device and the requirement for specialized operator training.

![3D reconstructed prostate model showing suspicious area identified on mpMRI, allowing targeted sampling of abnormalities in the prostate.](CEJU-69-00734-g002){#F0002}

### Hardware and software platforms for MRI-US fusion

A number of commercial platforms have become available for MRI-US-fusion. These applications vary by method of co-registration (mechanical, electromagnetic, or real-time) and utilize different hardware platforms for spatial tracking of the probe within the co-registered image ([Table 2](#T0002){ref-type="table"}). The general workflow of all platforms first requires segmentation of a pre-biopsy diagnostic MRI in axial and sagittal frames to allow construction of the 3-dimensional model. Each suspicious ROI is likewise segmented and annotated within the model. Then, depending on the particular platform, targets are delineated before or after MRI data have been loaded onto the software platform. The co-registration of the MRI to the US image can be performed either by rigid, elastic, or both methods, depending on the platform. Rigid fusion involves overlay of images allowing translation and rotation without change to the images themselves. Elastic fusion accounts for the addition of local deformation by stretching the image volumes and targeted lesion(s) resulting in matched borders \[[@CIT0034]\]. TRUS-guided biopsy of the prostate is performed and MRI and real-time TRUS images are superimposed and displayed side-by-side, thus creating an easily navigable three-dimensional prostate reconstruction. Because MRI and US images have been co-localized and co-registered, they allow blending back and forth between MRI and TRUS.

###### 

Summary of MRI-US fusion platforms

  System trade name (manufacturer)   US image acquisition               Image registration                   Biopsy route                   Tracking mechanism
  ---------------------------------- ---------------------------------- ------------------------------------ ------------------------------ ---------------------------------------
  UroNav (Philips, In Vivo)          Manual sweep from base to apex     Rigid                                Transrectal                    Electromagnetic tracking
  Artemis (Eigen)                    Manual rotation along fixed axis   Rigid and elastic                    Transrectal                    Mechanical arm with encoders
  Urostation (Koelis)                Automatic probe rotation           Elastic                              Transrectal                    Image-based (TRUS-TRUS) registration
  HI-RVS (Hitachi)                   Real-time biplanar TRUS            Rigid                                Transrectal or transperineal   External magnetic field generator
  BioJet (DK Technologies)           Manual sweep                       Rigid                                Transrectal or transperineal   Mechanical arm with encoders, stepper
  BiopSee (MedCom)                   Manual sweep with biplanar probe   Manual, marker based, or automatic   Transperineal                  Stepper with encoders

Clinical applications {#S20011}
---------------------

### No previous biopsy

In men presenting for first biopsy, the potential advantages of MRI-targeted biopsy are twofold: improving detection of high-grade cancer by reducing the false-negative rate of biopsy, and avoiding detection of low-grade disease by selectively targeting tumor foci which are more likely to be clinically significant. Several studies reporting outcomes of combined MRI-targeted biopsy and systematic biopsy among biopsy naive men have suggested the potential to achieve these goals using mp-MRI in the primary biopsy setting ([Table 3](#T0003){ref-type="table"}) \[[@CIT0035], [@CIT0039]\]. Delongchamps et al. compared outcomes of targeted and systematic biopsy among 391 men presenting for first biopsy. The investigators reported improved detection of high-grade cancer using targeted biopsy, which missed only 2/63 (3%) Gleason ≥7 cancers detected by systematic biopsy while detecting an additional 17 high grade cancers \[[@CIT0036], [@CIT0037]\]. Additionally, 39 Gleason 6 cancers identified on systematic biopsy were avoided by targeted biopsy. Pokorny et al. similarly observed that MRI-targeted biopsy increased the detection of intermediate/high-risk disease by 18% and decreased the diagnosis of low-risk cancer by 89% in a prospective trial of 223 men \[[@CIT0038]\]. Mendhiratta et al. observed a 15% increase in Gleason score ≥7 cancers by MRI-US fusion targeted biopsy as compared to systematic biopsy among 382 consecutive biopsy naive men \[[@CIT0039]\]. Additionally, the majority of cancers missed by targeted biopsy were clinically insignificant by Epstein (62%) and UCSF-CAPRA (82%) criteria, suggesting that systematic biopsy largely contributes to the detection of low-risk disease among biopsy naive men undergoing both targeted and systematic biopsies \[[@CIT0039]\].

###### 

Summary of trials of MRI-US fusion-targeted biopsy compared to systematic biopsy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Investigators                         Study size   Biopsy history                                 TB technique    SB technique            Definition of\                              Overall CDR (TB)   Overall CDR (SB)   Clinically\    Clinically\
                                                                                                                                            clinically\                                                                       significant\   significant\
                                                                                                                                            significant cancer                                                                CDR (TB)       CDR (SB)
  ------------------------------------- ------------ ---------------------------------------------- --------------- ----------------------- ------------------------------------------- ------------------ ------------------ -------------- --------------
  Meng et al. \[[@CIT0003]\]            601          49% BN\                                        Transrectal     12-core TRUS            GS ≥3+4                                     39%                40%                26%            19%
                                                     29% PNB\                                                                                                                                                                                
                                                     22% AS                                                                                                                                                                                  

  Mendhiratta et el. \[[@CIT0039]\]     382          100% BN                                        Transrectal     12-core TRUS            GS ≥3+4                                     24%                18%                16%            9%

  Mozer et al. \[[@CIT0063]\]           152          100% BN                                        Transrectal     12-core TRUS            CCL ≥4 mm or GS ≥3+4                        54%                57%                43%            37%

  Salami et al. \[[@CIT0042]\]          140          100% BN                                        Transrectal     12-core TRUS            Epstein criteria \[[@CIT0064]\]             52%                49%                48%            31%

  Siddiqui et al. \[[@CIT0065]\]        1003         20% BN\                                        Transrectal     12-core TRUS            GS ≥4+3                                     46%                47%                17%            12%
                                                     43% PNB\                                                                                                                                                                                
                                                     37% AS                                                                                                                                                                                  

  Sonn et al. \[[@CIT0066]\]            171          38% PNB\                                       Transrectal     12-core TRUS            GS ≥3+4                                     35%                44%                13%            12%
                                                     62% AS                                                                                                                                                                                  

  Rastinehad et al. \[[@CIT0067]\]      105          33% BN\                                        Transrectal     12-core TRUS            Epstein criteria \[[@CIT0064]\]             51%                49%                45%            32%
                                                     67% PNB                                                                                                                                                                                 

  Wysock et al. \[[@CIT0027]\]          125          54% BN\                                        Transrectal     12-core TRUS            GS ≥3+4                                     36%                NR                 23%            NR
                                                     27% PNB\                                                                                                                                                                                
                                                     19% AS                                                                                                                                                                                  

  Kuru et al. \[[@CIT0068]\]            347          51% BN\                                        Transperineal   24-core Transperineal   NCCN criteria (intermediate or high risk)   51%                50%                41%            38%
                                                     49% PNB                                                                                                                                                                                 

  Delongchamps et al. \[[@CIT0036]\]\   131          100% BN                                        Transrectal     12-core TRUS            CCL ≥ 4 mm or GS ≥ 3+4                      49%                46%                NR             NR
  (Rigid fusion)                                                                                                                                                                                                                             

  Delongchamps et al. \[[@CIT0036]\]\   133          100% BN                                        Transrectal     12-core TRUS            CCL ≥ 4 mm or GS ≥ 3+4                      47%                33%                NR             NR
  (Elastic fusion)                                                                                                                                                                                                                           

  Fiard et al. \[[@CIT0069]\]           30           43% BN\                                        Transrectal     12-core TRUS            ≥ 10 mm cancer or GS ≥ 3+4                  55%                43%                50%            33%
                                                     57% PNB                                                                                                                                                                                 

  Sonn et al. \[[@CIT0041]\]            105          100% PNB                                       Transrectal     12-core TRUS            CCL ≥ 4 mm or GS ≥ 3+4                      24%                28%                22%            15%

  Rud et al. \[[@CIT0070]\]             90           12% BN\                                        Transrectal     12-core TRUS            GS ≥ 3+4                                    68%\               14%\               46%\           5%\
                                                     88% Repeat[\*](#TF0001){ref-type="table-fn"}                                                                                       (54/80)            (6/42)             (37/80)        (2/42)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TB -- MR-targeted biopsy; SB: systematic biopsy; BN -- biopsy naive; PNB -- prior negative biopsy; AS: active surveillance; CCL -- cancer-core length; GS -- Gleason score

62/90 (69%) men presented for repeat biopsy without prior treatment for cancer, while 17/90 (19%) men had biochemical recurrence after radiation therapy for previously diagnosed cancer.

### Prior negative biopsy

Men with prior negative biopsies often present for repeat biopsy as a consequence of the limited negative predictive value of a negative systematic biopsy \[[@CIT0040]\]. Among this population of men, the advantage of MRI-targeted biopsy is in identifying areas of suspicion within the prostate which would otherwise be missed by repeat systematic sampling, as several recent series have demonstrated ([Table 3](#T0003){ref-type="table"}) \[[@CIT0041], [@CIT0042], [@CIT0043]\]. Sonn et al. observed that targeted biopsy detected more clinically significant cancers and fewer clinically insignificant cancers than systematic biopsy in a series of 105 consecutive men \[[@CIT0041]\]. Among 140 men, Salami et al. observed higher detection rates of clinically significant cancer by targeted biopsy compared to systematic biopsy (48% *vs*. 31%), and additionally noted that only 3.5% of clinically significant cancers would have been missed by targeted biopsy alone in this cohort. In a study of 161 men with a prior negative biopsy, Mendhiratta et al. found MRI fusion targeted biopsy to detect more Gleason score ≥7 disease (14.9% compared to systematic (9.35, p = 0.02) \[[@CIT0044]\]. Using UCSF-CAPRA criteria, only one man was re-stratified from low-risk to higher risk based on systematic results compared to MRI fusion targeted biopsy alone. In light of evidence suggesting a clinical benefit of targeted biopsy for men with prior negative biopsies, the NCCN guidelines for prostate cancer detection have suggested that men with two or more prior negative biopsies who present for repeat biopsy should undergo pre-biopsy mp-MRI to identify areas of occult disease \[[@CIT0045]\].

### Prior positive biopsy

Prostate mp-MRI may have two applications in men with a prior positive prostate biopsy. First, it improves risk stratification for selecting appropriate candidates for active surveillance (AS) by allowing the identification and targeting of MRI lesions with biopsy, ultimately ruling out clinically significant disease. Secondly, it reduces the need for repetitive biopsy through non-invasive serial monitoring for those on active surveillance.

Including mp-MRI into disease characterization strategies improves risk stratification by identifying disease typically missed on standard biopsy ([Table 3](#T0003){ref-type="table"}) \[[@CIT0001], [@CIT0046], [@CIT0047]\]. The presence of mp-MRI lesions significantly increased the probability of Gleason score upgrade on repeat systematic biopsy \[[@CIT0048], [@CIT0049]\]. Furthermore, several series report disease reclassification rates of 17--36% when mp-MRI with targeted biopsy is utilized for surveillance biopsy on men enrolled on active surveillance by prior Epstein criteria \[[@CIT0048], [@CIT0050], [@CIT0051], [@CIT0052], [@CIT0053]\]. Findings on mp-MRI predicting disease reclassification include number of lesions, MRI suspicion score and lesion density \[[@CIT0053], [@CIT0054]\]. Stamatakis et al. have published a nomogram predicting probability of meeting AS criteria based upon MRI characteristics \[[@CIT0053]\]. It has also been shown that MRI may reasonably decrease the number of repeat biopsies in patients on active surveillance by as much as 68% \[[@CIT0055]\]. Conversely, disease reclassification for men on AS with normal mp-MRI appears to be very low with negative predictive value ranges from 81--90% \[[@CIT0049], [@CIT0051], [@CIT0056]\]. These findings provide compelling rationale for the incorporation of mp-MRI and targeted biopsy into active surveillance selection criteria.

Observable changes in disease characteristics on mp-MRI would offer a novel, non-invasive method for following disease progression. Early data regarding serial imaging of lesions report that 45.4% of men with lesions at baseline will demonstrate progression on imaging (increase in lesion volume or conspicuity; defined as DWI of lesion/DWI of normal prostate). In contrast, only 17% of those without visible lesions demonstrated radiographic progression \[[@CIT0057]\]. Another study reported a similar finding of three times overall risk of cancer progression for men with abnormal findings on mp-MRI \[[@CIT0058]\]. The time interval for changes in mp-MRI was evaluated in a cohort of men with small index lesions (≤7 or ≤5 mm). No change in size was noted over a period of approximately 2 years \[[@CIT0059]\]. Data from the MAPPED study may provide additional insight into temporal changes in MRI findings \[[@CIT0060]\]. Finally, early data on serial mp-MRI with targeted biopsy amongst men on AS demonstrated a negative predictive value of 80% for stable MRI findings \[[@CIT0061]\]. MRI-US fusion biopsy techniques allow for disease mapping and provide templates for repeat biopsy both in locations of disease diagnosed with targeted biopsy but also with standard biopsy. Initial data regarding repeat fusion biopsy of mp-MRI targets demonstrated increased cancer detection when compared to standard repeat biopsy \[[@CIT0062]\]. In summary, mp-MRI with targeted biopsy can provide improved risk stratification for selecting appropriate candidates for AS. The impact of mp-MRI and further targeted biopsy for those on active surveillance remains to be determined.

CONCLUSIONS {#S0015}
===========

Use of mp-MRI for targeting prostate biopsies has the potential to reduce the sampling error associated with conventional biopsy by providing better disease localization and sampling. MRI-US targeted prostate biopsy may improve the detection of clinically significant prostate cancer while limiting detection of indolent disease, ultimately increasing accurate risk stratification. Literature supports the clinical applications of MRI-targeted biopsy in men who are biopsy naïve, those with a prior negative biopsy, and those on with low risk disease considering active surveillance.
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